Drug intelligence / Profile preview

trivalent oral poliovirus vaccine Bio Farma

Development stage
Discontinued
Lead developer
Bio Farma
Modality
Vaccines & Immunotherapeutics
Administration
Oral
01

Overview

**Trivalent oral poliovirus vaccine Bio Farma** is a live-attenuated oral poliomyelitis vaccine developed and manufactured by Bio Farma for active immunization against poliovirus types 1, 2, and 3. It contains attenuated Sabin-strain polioviruses and induces serotype-specific mucosal and systemic immune responses, including neutralizing antibodies, to prevent poliomyelitis. A Bio Farma-sponsored Phase II randomized, double-blind study evaluated immunogenicity and safety across pilot and commercial vaccine batches in Indonesian infants. Trivalent OPV was withdrawn from routine use globally during the April 2016 OPV switch and replaced by bivalent OPV plus inactivated poliovirus vaccine strategies after eradication of wild poliovirus type 2. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02093273))

Other names
tOPV Bio Farmatrivalent oral polio vaccine Bio Farma

Beyond the preview

Go deeper on trivalent oral poliovirus vaccine Bio Farma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on trivalent oral poliovirus vaccine Bio Farma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call